Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Tumor microenvironment signaling and therapeutics in cancer progression
Anshika Goenka, Fatima Khan, Bhupender Verma, et al.
Cancer Communications (2023) Vol. 43, Iss. 5, pp. 525-561
Open Access | Times Cited: 122
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
Mohamed El‐Tanani, Syed Arman Rabbani, Rasha Babiker, et al.
Cancer Letters (2024) Vol. 591, pp. 216894-216894
Open Access | Times Cited: 46
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
Alex G. Hamilton, Kelsey L. Swingle, Ryann A. Joseph, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 30
Open Access | Times Cited: 45
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
Metin Özdemirli, Thomas M. Loughney, Emre Deniz, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 22, pp. 2074-2082
Closed Access | Times Cited: 35
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 32
CAR-NK cells for cancer immunotherapy: recent advances and future directions
Tianye Li, Mengke Niu, Weijiang Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 24
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
New insights into the role of macrophages in cancer immunotherapy
Zhou Li, Tiantian Zhao, Ruzhe Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 19
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)
Dahua Sun, Xiang Shi, Sanyan Li, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 18
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer
Jia Han, B. Zhang, Senyu Zheng, et al.
Cell Transplantation (2024) Vol. 33
Open Access | Times Cited: 17
Targeting triple negative breast cancer stem cells using nanocarriers
Nagasen Dasari, Girijasankar Guntuku, Sai Kiran S. S. Pindiprolu
Discover Nano (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 17
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Shan Muhammad, Tao Fan, Yang Hai, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 41
Extracellular vesicle–based drug delivery in cancer immunotherapy
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 11, pp. 2790-2806
Open Access | Times Cited: 38
The tumor microenvironment: shaping cancer progression and treatment response
Sharav Desai, Vipul P. Patel, Kunal Bhosle, et al.
Journal of Chemotherapy (2024), pp. 1-30
Closed Access | Times Cited: 13
The potential and promise for clinical application of adoptive T cell therapy in cancer
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Jing Li, Ping Chen, Wenxue Ma
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Smart Nanoscale Extracellular Vesicles in the Brain: Unveiling their Biology, Diagnostic Potential, and Therapeutic Applications
Akanksha Onkar, Fatima Khan, Anshika Goenka, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 6, pp. 6709-6742
Closed Access | Times Cited: 10
Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
Pengfei Zhang, Dan Xie
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
Crismita Dmello, Junfei Zhao, Li Chen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy
Keyan Miao, Weici Liu, Jingtong Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Recent Advances in Cancer Immunotherapy Delivery Modalities
Palaniyandi Muthukutty, Hyun Young Woo, Murali Ragothaman, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 504-504
Open Access | Times Cited: 19
Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers
Xiaoshuai Zhang, Haiyan Guo, Jie Chen, et al.
Cancer Letters (2023) Vol. 572, pp. 216355-216355
Open Access | Times Cited: 17
High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route
Alex G. Hamilton, Kelsey L. Swingle, Ajay S. Thatte, et al.
ACS Nano (2024) Vol. 18, Iss. 25, pp. 16151-16165
Closed Access | Times Cited: 8
Harnessing the evolving CRISPR/Cas9 for precision oncology
Tianye Li, Shuiquan Li, Yue Kang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
Xianfei Liu, Masanori Onda, Jerome Schlomer, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 4
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top